Abstract Background Nocturia is considered as one of the commonest nonmotor symptoms in people with Parkinson's disease ( PD ), highly impacting on quality‐of‐life and health‐related costs. Objectives Aim of our real‐world study was to evaluate the impact of Foslevodopa/Foscarbidopa ( LDp / CDp ) subcutaneous infusion ( CSCI ) on nocturia in a group of advanced PD patients. Methods Seventy‐eight patients were enrolled in seven Movement Disorders outpatient clinics. International Prostatic Symptoms Scale ( IPSS ) and Nocturia Quality of Life ( NQoL ) questionnaire were administrated before starting LDp / CDp CSCI and after three months of infusion. Results In this cohort, LDp / CDp CSCI significantly improved urinary disturbances, nocturia and quality of life. Age and baseline MDS ‐ UPDRS score negatively influenced urinary disturbances and quality of life changes during the treatment, while post‐pre changes of IPSS and LEED showed a negative correlation. Conclusions This study supports the utility of the overnight dopaminergic stimulation with LDp / CDp CSCI in controlling overactive bladder.
Brusa et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: